InsiderTrades

Form 4 for XERS Xeris Biopharma Holdings, Inc.

Accepted 2024-08-02 00:00:00 ET · period of report 2022-01-29 · accession 0001867096-24-000145 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-08-02 2022-01-29+ XERS Shannon John Patrick Jr See Remarks, Dir F - Tax $2.06 -271.6K 2.32M -10% -$559.8K
D 2024-08-02 2024-08-01 XERS Shannon John Patrick Jr See Remarks, Dir A - Grant $0.00 +250.0K 2.42M +12% $0
D 2024-08-02 2024-08-01 XERS Shannon John Patrick Jr See Remarks, Dir A - Grant $0.00 +300.0K 300.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-31 F D 7,497 $2.11 2,396,423 D — — (F3) This transaction is being reported late due to administrative oversight. (F5) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
2 Common Common Stock 2023-01-03 F D 41,334 $1.12 2,355,089 D — — (F3) This transaction is being reported late due to administrative oversight. (F6) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
3 Common Common Stock 2023-01-29 F D 23,414 $1.26 2,331,675 D — — (F3) This transaction is being reported late due to administrative oversight. (F7) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
4 Common Common Stock 2024-01-03 F D 40,834 $2.24 2,280,961 D — — (F3) This transaction is being reported late due to administrative oversight. (F9) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
5 Common Common Stock 2024-01-29 F D 22,150 $2.66 2,258,811 D — — (F3) This transaction is being reported late due to administrative oversight. (F10) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
6 Common Common Stock 2024-01-31 F D 110,750 $2.46 2,148,061 D — — (F3) This transaction is being reported late due to administrative oversight. (F11) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
7 Common Common Stock 2024-08-01 A A 250,000 $0.00 2,419,612 D — — (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. (F2) These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
8 Common Common Stock 2022-01-29 F D 15,692 $2.11 2,403,920 D — — (F3) This transaction is being reported late due to administrative oversight. (F4) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
9 Common Common Stock 2023-01-31 F D 9,880 $1.24 2,321,795 D — — (F3) This transaction is being reported late due to administrative oversight. (F8) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
10 Derivative Stock Appreciation Right 2024-08-01 A A 300,000 $0.00 300,000 D $2.43 · — to 2026-09-01 300,000 Common Stock (F12) The award will vest in full on the two-year anniversary of the grant date.